🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Christian Rolfo

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ORCID: 0000-0002-7860-8417

Also affiliated with Icahn School of Medicine at Mount Sinai

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study”.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

The Lancet Oncology(2023)10.1016/s1470-2045(23)00344-3

N/A

3.1DataRank · unranked

105 citations

Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo +20 more

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Investigational New Drugs(2024)10.1007/s10637-023-01410-2

N/A

1.3DataRank · unranked

67 citations

Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen +12 more

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Journal of Experimental & Clinical Cancer Research(2022)10.1186/s13046-022-02379-1

N/A

0.710DataRank · unranked

113 citations

Alessandro Russo, Óscar Arrieta, Murat Ak, Feliciano Barrón, Muthukumar Gunasekaran +20 more

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Vaccines(2024)10.3390/vaccines12070713

N/A

0.104DataRank · unranked

1 citations

Chih–Yuan Hsu, Ananda M. Rodilla, Jorge Gómez, Jazz Cagan, Yuanhui Huang +19 more

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.11.001

N/A

0DataRank · unranked

54 citations

Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo Garcı́a-Sastre, Philip C. Mack +14 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004

N/A

0DataRank · unranked

57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928

N/A

0DataRank · unranked

16 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4097

N/A

0DataRank · unranked

4 citations

Aurora O’Brate, Christoph Menzel, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh +3 more

Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies

The Journal of Liquid Biopsy(2025)10.1016/j.jlb.2025.100442

N/A

0DataRank · unranked

2 citations

Moh’d Khushman, Alessandro Russo, Roberto Borea, Bernard Herrman, Jing Wang +7 more

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Cancers(2020)10.3390/cancers12020284

N/A

0DataRank · unranked

14 citations

Xinxin Xiong, Christian Rolfo, Xuexiang Du, Yan Zhang, Han Yang +6 more

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Lung Cancer(2025)10.1016/j.lungcan.2025.108802

N/A

0DataRank · unranked

1 citations

David E. Gerber, Rupesh Kotecha, Jeffrey P. Ward, Wallace Akerley, Lukas Weiß +5 more

First-in-human phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3159

N/A

0DataRank · unranked

1 citations

Søren M. Bentzen, Martin Devenport, Yang Liu, Pan Zheng, Christian Rolfo

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.017

N/A

0DataRank · unranked

654 citations

Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési +23 more

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001752

N/A

0DataRank · unranked

54 citations

Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey +13 more